Introduction
The World Health Organization estimated that 422 million adults suffered from diabetes in 2014 and 1.5 million deaths could be DOI: 10.1002/mnfr.201800373 directly attributed to this pathology in just one year (2012) . Most of the population suffering from diabetes is affected by type 2 diabetes (T2D). T2D is preceded by insulin resistance (IR): a reduced capacity to internalize glucose from the bloodstream as a result of insensitivity to insulin that may result from genetic predisposition, physical inactivity, and/or obesity in both rats and humans. [1] IR brings about an increase in pancreatic insulin secretion from a greater number or size of pancreatic β-cells, which compensates the low insulin sensitivity. Then, if IR proceeds further into diabetes, a drop in insulin secretion follows, with subsequent increased fasting glucose levels and impaired glucose tolerance (IGT; high glucose levels 2 h after ingestion) as a consequence of a loss and dedifferentiation of pancreatic β-cells. [1] Three main mechanisms have been proposed to explain the pathogenesis of IR in different organs: endoplasmic reticulum stress with the activation of the unfolded protein response, ectopic lipid accumulation with impairment of intracellular signaling patterns by particular lipid mediators, and systemic inflammation. [2] More recently, systemic inflammation, IR, and obesity have been linked to shifts in the populations of gut microbiota (gut "dysbiosis").
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The major bacterial phyla in distal gut microbiota are Bacteroidetes and Firmicutes. A reduction in the ratio between these two phyla has been related to weight gain by the host. [4, 5] Also, an increase in the population of Enterobacteriales has been associated with diet-induced obesity. [6] A common antecedent that may link dysbiosis, obesity, and IR is the induction of plasmatic endotoxemia, [7] which may trigger low-grade inflammation and/or changes in energy harvest capacity. [8, 9] Other minor gut bacterial subgroups such as Lactobacillus and Bifidobacterium may help to maintain host homeostasis. [10] Specifically, high levels of Bifidobacterium reduce diet-induced IR and inflammation. [11, 12] d-Fagomine (1,2-dideoxynojirimycin) is an iminosugar: a carbohydrate analog that includes an endocyclic nitrogen instead of oxygen. [13] d-Fagomine is naturally present in buckwheat (Fagopyrum esculentum Moench, Polygonaceae) and can be found in several buckwheat-based foodstuffs such as noodles, pancakes, fried dough, beer, cookies, and bread. [14] d-Fagomine lowers postprandial blood glucose in sucrose/starch loading tests [15] and it reduces elevated plasma insulin concentrations induced by a highfat high-sucrose diet in the short term (9 weeks). [16] This study examines the long-term functional effect of dfagomine on a fat-induced prediabetic state and explores possible molecular mechanisms behind its action.
Experimental Section

Animals
A total of 27 male Wistar Kyoto (WKY) rats from Envigo (Indianapolis, IN, USA), aged 8-9 weeks were used. All the procedures strictly adhered to the European Union guidelines for the care and management of laboratory animals, and were under license from the Catalan authorities (reference no. DAAM7921), as approved by the Spanish CSIC Subcommittee of Bioethical Issues.
Experimental Design: Data and Sample Collection
The rats were kept under controlled conditions of humidity (60%), and temperature (22 ± 2°C) with a 12 h light-12 h dark cycle. They were randomly divided into three dietary groups (n = 9 per group): the standard (STD) group, fed an STD diet (2014 Teklad Global 14% Protein) from Envigo; the high-fat (HF) group fed an HF diet (TD.08811 45% kcal Fat) from Envigo; and the group fed the HF diet supplemented with 0.96 g of d-fagomine (>98% from Bioglane SLNE; Barcelona, Spain) per kg of feed (HF+FG group). The dose of d-fagomine corresponded to that used in postprandial sucrose/starch loading tests (2 mg g −1 sucrose). [15] All the groups were fed ad libitum with free access to water.
Feed consumption was monitored daily and body weight was measured weekly throughout the experiment. Energy intake was calculated as estimates of metabolizable energy based on the Atwater factors, assigning 4 kcal g −1 protein, 9 kcal g −1 fat, and 4 kcal g −1 available carbohydrate. Fecal samples were collected by abdominal massage at weeks 9, 20, and 24. The energy content of the feces from week 20 was determined by differential scanning calorimetry (25-600°C in an O 2 atmosphere, 10°C min −1 ) by means of a thermogravimetric analyzer TGA/SDTA 851e (Mettler Toledo; Columbus, OH, USA) with an integrated SDTA signal.
At weeks 10 and 16, blood samples were collected from the saphenous vein after overnight fasting, and plasma was separated by centrifugation and stored at −80°C until analysis.
At the end of the experiment, the rats were fasted overnight and anesthetized intraperitoneally with ketamine and xylazine (80 and 10 mg per kg body weight, respectively). Blood was collected by cardiac puncture, then plasma was immediately obtained by centrifugation and stored at −80°C until analysis. Perigonadal adipose tissue (AT), liver, and quadriceps (muscular tissue) were removed, weighed, and cut into small pieces. One part of the liver was fixed in 10% formalin for histological analysis. The rest of the liver as well as the muscle and AT samples were washed with 0.9% NaCl solution and stored at −80°C for diacylglycerol (DAG) analysis.
Plasma Lipid Profile
Plasma total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides were measured using a spectrophotometric method and the corresponding kits from Spinreact (Girona, Spain) as described by Bucolo et al. [17, 18] 
Plasma Insulin, Glucose, and Oral Glucose Tolerance test
Plasma insulin levels were measured using MILLIPLEX xMAP multiplex technology on a Luminex xMAP instrument (Millipore, Austin, TX, USA) at weeks 10 and 16. MILLIPLEX Analyst 5.1 (VigeneTech, Carlisle, PA, USA) software was used for data analysis. The standard curve was generated in the range 69-50 000 pg mL −1 . At weeks 13 and 21, an oral glucose tolerance test (OGTT) was performed on fasted animals. A solution of glucose (1 g per kg body weight) was administered to the rats by oral gavage. Blood glucose concentration was measured by the enzyme electrode method using an Ascensia ELITE XL blood glucose meter (Bayer Consumer Care AG; Basel, Switzerland) before the experiment and 15, 30, 45, 60, 90, and 120 min after glucose intake. Fasting glucose concentration was measured by the same method at weeks 10 and 16.
Diacylglycerols in Perigonadal Adipose Tissue, Liver, and Muscle
Frozen samples were weighted and sonicated (SFX150 Sonifier; Emerson Industrial Automation, St. Louis, MO, USA) until total homogenization. DAG extracts were prepared and analyzed using the method described by Simbari et al. [19] with some modifications. The mixtures were fortified with an internal standard (1,3-17:0 D5 DG, Avanti Polar Lipids Inc., Alabaster, AL, USA; 200 pmol) and incubated overnight at 48°C. After solvent evaporation, the samples were suspended in methanol, centrifuged www.advancedsciencenews.com www.mnf-journal.com (9390 g, 3 min), and the supernatants were loaded into an Acquity UPLC system connected to an LCT Premier orthogonal accelerated time-of-flight mass spectrometer (Waters, Milford, MA, USA), which was operated in positive ESI mode (LC-TOF-MS). Full-scan spectra from 50 to 1500 Da were acquired, and individual spectra were summed to produce data points of 0.2 s each. Mass accuracy and precision were maintained by using an independent reference spray (leucine enkephalin) via the LockSpray interference. A C8 Acquity UPLC-bridged ethylene hybrid 100 × 2.1 mm inner diameter, 1.7 μm column (Waters) was used in the separation step. The samples (8 μL 
Liver and Adipose Tissue Histology
Fixed liver and AT were dehydrated in alcohol and embedded in paraffin (Panreac Quimica SLU; Barcelona, Spain), then cut into 3 μm thick slices, using a steel knife mounted in a microtome (HM 355S Rotary Microtome; Thermo Fisher Scientific, Waltham, MA, USA). Sections were stained with hematoxylin (hematoxylin solution modified in accordance with Gill III for microscopy; Merck KGaA, Darmstadt, Germany)/eosin (Pharmacy Service of Puerta del Mar Hospital, Cádiz, Spain) then viewed under a light microscope (NIKON Eclipse 80i; NIKON Corporation, Minato, Japan). Variables were graded following the method described by Taltavull et al. [20] using observation of the entire field of the tissue preparations. Liver: steatosis, 0 (<5%), 1 (5-33%), 2 (33-66%), or 3 (>66%); steatosis localization, 0 (absence), 1 (periportal), and 2 (non-zonal); lobular inflammation with lymphoplasmacytic inflammatory infiltration, 0 (absence), 1 (1-2 foci), 2 (2-4 foci), or 3 (>4 foci); and the presence of microgranulomas, 0 (absence) or 1 (presence). AT: adipocyte hypertrophy, 0 (absence) or 1 (presence); macrophages 0 (absence) or 1 (presence); mast cells, 0 (absence) or 1 (presence); and adipose tissue inflammation with lymphoplasmacytic inflammatory infiltration, 0 (absence) or 1 (presence).
Biomarkers and Lipid Mediators of Inflammation in Plasma
Plasma IL-6 and leptin levels were measured using MILLIPLEX xMAP multiplex technology (Millipore) on a Luminex xMAP instrument.
Plasma lipopolysaccharides (LPS) concentration was estimated by reaction with Limulus amoebocyte extract: LAL kit end point-QCL1000 (Cambrex BioScience, Walkersville, MD). Plasma samples collected at the end of the study under sterile conditions were diluted 70-fold and heated for 20 cycles of 10 min at 68°C and 10 min at 4°C each. An internal control for LPS recovery was included.
Lipid mediators derived from arachidonic acid (ARA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) were determined in plasma using a method modified from Dasilva et al. [21] Briefly, plasma samples (90 μL) were diluted in cold 0.05% butylated hydroxytoluene (BHT) in methanol/water (3:7) (1 mL) and spiked with the internal standard (12HETE-d8, Cayman Chemicals; Ann Arbor, MI, USA). Then, the samples were centrifuged (Avanti J25, Beckman Coulter; Brea, CA, USA) (800 g, 10 min) at 4°C. The supernatants were purified by solid-phase extraction.
The LC-MS/MS analyzer used was an Agilent 1260 Series (Agilent; Palo Alto, CA, USA) chromatograph coupled to an LTQ Velos Pro dual-pressure linear ion trap mass spectrometer (Thermo Fisher; Rockford, IL, USA) operated in negative ESI mode. A C18-Symmetry 150 × 2.1 mm inner diameter, 3.5 μm column (Waters) was used with a C18 4 × 2 mm guard cartridge (Phenomenex; Torrance, CA, USA) in the separation step. Samples (10 μL) were eluted with a binary system of 0.02% formic acid in water [A] and in methanol [B] . The gradient was: 1 min, 60% B; 2 min, 60% B; 12 min, 80% B; 13 min, 80% B; 23 min, 100% B; 25 min, 100% B; and 30 min, 60% B. The flow rate was 0.2 mL min −1 . LC-MS/MS details are provided in Table S1 , Supporting Information.
Fecal Microbiota
The levels of total bacteria and Bacteroidetes, Firmicutes, Enterobacteriales, Bifidobacteria, and Lactobacilliales were estimated from fecal DNA by quantitative real-time PCR (qRT-PCR). DNA was extracted from the feces using QIAamp DNA Stool Mini Kit from Qiagen (Hilden, Germany) and its concentration was quantified using a Nanodrop 8000 Spectrophotometer (Thermo Scientific; Waltham, MA, USA). All DNA samples were diluted to 20 ng μL −1 . The qRT-PCR experiments were carried out using a LightCycler 480 II (Roche; Basel, Switzerland).
Each qRT-PCR well was run in triplicate and contained a total of 20 μL: 18 μL of Master Mix (10 μL of 2X SYBR, 1 μL of each [ forward and reverse] corresponding primer, and 6 μL of water) and 2 μL of DNA sample. All reactions were paralleled by analysis of a nontemplate control (water) and a positive control. The primers and annealing temperatures are detailed in Table S2 , Supporting Information.
The qRT-PCR cycling conditions were: 10 s at 95°C, then 45 cycles of 5 s at 95°C, 30 s at primer-specific annealing temperature (Table S2 , Supporting Information), and 30 s at 72°C (extension). Following amplification, to determine the specificity of the qRT-PCR, melting curve analysis was carried out by treatment for 2 s at 95°C, 15 s at 65°C, and then continuous increase of temperature up to 95°C (0.11°C s −1 ), with five fluorescence recordings per degree Celsius. The relative DNA abundances for the different genes were calculated from the second derivative maximum of their respective amplification curves (Cp, calculated in triplicate) by considering Cp values to be proportional to the dual logarithm of the inverse of the specific DNA concentration, according to the equation:
Cpb-Cpa . [22] Total bacteria was normalized as 16S rRNA gene copies per mg of wet feces (copies per mg). 
Statistical Analysis
All data manipulation, statistical analysis, and figure construction were performed using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA). The results of the quantitative measurements are expressed as mean values with their standard errors (SEM). Normal distributions and the heterogeneity of data were evaluated and their statistical significance was determined by one-or two-way ANOVA, and Tukey's multiple comparison test was used for mean comparisons. The results from qualitative measurements (histology) are expressed in frequencies (percentage of animals that present the variable, or do not) and their statistical significance was determined using contingency tables and χ 2 statistics. Differences were considered significant when P < 0.05 and were considered to indicate a tendency when 0.05 < P < 0.1.
Results
Feed Intake, Body Weight, and Lipid Profile
Feed/energy intake and body weight were monitored throughout the study (Table 1 ; Figure S1 , Supporting Information). Rats fed the two high-energy-dense diets (HF and HF+FG) consumed significantly less feed (P < 0.05) and more energy (P < 0.05) than those in the STD group (Table 1) . Based on feed intake, the mean daily dose of d-fagomine was 2.9 mg per 100 g body weight. As observed in previous studies, d-fagomine supplementation did not modify feed intake. [16] The energy excreted, proportional to the SDTA signal obtained by thermal analysis, was similar in both the STD and HF groups and significantly higher (P < 0.05) in animals fed HF and d-fagomine. This result may be explained by the inhibitory activity of d-fagomine on intestinal disaccharidases, [15] which would result in the excretion of some undigested sucrose.
Body weight was similar in all the groups at the beginning (236.1 g, SEM 3.2). After 7 weeks, body weight in the HF group (374.3 g, SEM 10.0) was significantly higher (P < 0.05) than in the STD group (320.3 g, SEM 9.1); while the body weight increase in the HF+FG group only reached statistical difference (P < 0.05) with respect to the STD group 5 weeks later: after 12 weeks of diet ( Figure S1 , Supporting Information). At the end of the study, the HF group gained 29% more weight than those given the STD diet (537.9 g, SEM 15.1 vs 416.4 g, SEM 12.9 STD group) while animals supplemented with d-fagomine showed a tendency to gain less weight (20%: 499.9 g, SEM 15.7, P = 0.06 vs the HF group) ( Table 1 ). The plasma lipid profile presented values within normal ranges with some differences between groups (Table S3 , Supporting Information).
Glycemic Status
Fasting plasma glucose and insulin were measured at weeks 10, 16, and at the end of the study (Figure 1) . Fasting glucose levels in the HF group were higher (P < 0.001) than those in the STD group ( Figure 1A ) already from week 10. d-Fagomine supplementation reduced this increase from week 16 to levels similar to those in the STD group (P < 0.05 vs the HF group at week 21; Figure 1A ). Fasting glucose levels were below 80 mg dL −1 in all the groups at all times. Fasting plasma insulin was higher in both groups fed the HF diet at weeks 10 and 16 (P < 0.05; Figure 1B) . At the end of the study (week 24), insulin levels in the HF group dropped significantly (P < 0.05) while the group supplemented with d-fagomine still presented significantly higher insulin concentrations (P < 0.01; Figure 1B) .
The OGTT was performed twice during the study, after 13 and 21 weeks (Figure 2) . In the first test, the levels of postprandial glucose in the HF group were significantly (P < 0.001) higher than those in the other two groups (STD and HF+FG) 30, 45, and 60 min after administration, with levels of ࣙ140 mg dL −1 (Figure 2A) . The area under the curve (AUC) corresponding to the HF group was significantly greater (P < 0.001) than that for the STD and HF+FG groups, which presented no significant differences. By the end of the study (week 21, Figure 2B ), plasma glucose concentrations in the group supplemented with d-fagomine were still lower than those in the HF group, but only significantly lower (P < 0.05) 30 min after glucose intake. The AUC for the HF+FG and STD groups were not significantly different.
Biomarkers and Lipid Mediators of Inflammation in Plasma
Plasma concentration of IL-6 after 10 and 16 weeks of intervention was higher in animals fed HF diets (P < 0.05) than in animals fed the STD diet ( Table 2) . d-Fagomine showed a tendency (P = 0.07) to reduce the levels of plasma IL-6 at week 16. The plasma leptin concentration was higher in both groups fed HF diets (P < 0.01) than in the STD group. Comparisons were performed using one-way ANOVA and Tukey's tests. * P < 0.05, ** P < 0.01 and *** P < 0.001 vs STD group, δ P < 0.05 vs HF group. (Table 2 ) compared to the STD group.
LPS concentration increased significantly in HF+FG group
The levels of ARA-derived pro-inflammatory eicosanoids as well as eicosanoids and docosanoids derived from EPA and DHA, respectively, were measured by LC-MS/MS in plasma samples collected at the end of the study ( Table 2 ). The plasma concentration of prostaglandin E2 (PGE2) significantly increased in the HF group (P < 0.05) compared to the STD group. The levels of pro-inflammatory PGE 2 and leukotriene B4 (LTB4) were similar in the STD and HF+FG groups. No differences were detected in the levels of other eicosanoids or docosanoids (Table 2) .
Diacylglycerols in Perigonadal Adipose Tissue, Liver, and Muscle
IR-related intracellular signaling lipid mediators DAGs were measured in perigonadal AT, liver, and muscle by LC-TOF-MS from the samples taken at the end of the study (Figure 3) . There was no increase in the amounts of total DAGs or in some of the relevant structures, namely DAG 34:1 (putatively 1-palmitoyl-2-oleoyl-sn-glycerol), DAG 36:2 (putatively 1-stearoyl-2-linoleoyl-snglycerol), and DAG 38:4 (putatively 1-stearoyl-2-arachidonoyl-snglycerol) in the HF group compared to the STD one. The levels of total DAGs in AT as well as of DAG 34:1 in AT and DAG 38:4 in AT and muscle were even significantly lower in the HF group. d-Fagomine supplementation did not induce any significant change in the levels of DAGs with respect to the HF group.
Liver and Adipose Tissue Histology
Steatosis, lobular inflammation, and microgranulomas were determined in liver by histology (Figure 4) . Neither high-fat diet induced steatosis to any significant extent. The inflammation and microgranulomas of animals fed HF were significantly higher (P < 0.001) than those of the STD and HF+FG groups ( Figure 4D ). The livers sections obtained from animals in the HF group showed lobular inflammation with lymphoplasmacytic inflammatory infiltration around the blood vessels (e.g., Figure 4B ). In contrast, such infiltration was scarce and smaller in extent in sections from livers pertaining to the group supplemented with d-fagomine (e.g., Figure 4C ).
Adipocytes were larger in the AT of animals fed the HF diets than the STD group ( Figure S2A ,B,D, Supporting Information); while no differences were detected between the HF and HF+FG groups ( Figure S2B ,C, Supporting Information). AT inflammation was not detected in any of the groups ( Figure S2G , Supporting Information).
Subpopulations of Gut Microbiota
The relative proportions of several bacterial groups of the gut microbiota were evaluated at weeks 9 and 24 ( Figure 5 ). The Bacteroidetes:Firmicutes ratio ( Figure 5F ) was significantly reduced (P < 0.01) in both high-fat diet groups and the presence of d-fagomine in the diet made no difference. The proportion of Enterobacteriales ( Figure 5C ,G) significantly (P < 0.05) increased in the HF group with respect to the STD group. The increase observed in the group supplemented with d-fagomine was not significant. The relative populations of Bifidobacteriales decreased as the animals grew older (P < 0.01 vs STD week 9; Figure 5D ,H) and some differences were detected between the groups. The HF diet significantly reduced the population of Bifidobacteriales already at week 9 (P < 0.05) independently of supplementation while d-fagomine showed a tendency to counteract the age-and diet-related losses of Bifidobacteriales that was only significant (P < 0.05) at the end of the intervention (week 24).
Discussion
The present study examines the long-term functional effects of d-fagomine on the preservation of glucose/insulin homeostasis and explores possible mechanisms of action for them in a rat model of diet-induced prediabetes. The prediabetic state was induced in male Wistar Kyoto rats by feeding them an HF diet and the effects of d-fagomine were observed over a period of 24 weeks. In agreement with preceding short-term studies (5 and 9 weeks) www.advancedsciencenews.com www.mnf-journal.com Comparisons were performed using one-way ANOVA and Tukey's tests or two-way ANOVA. ** P < 0.01 and *** P < 0.001 vs STD group, δ P < 0.05, δδ P < 0.01 and δδδ P < 0.001 vs HF group. Comparisons were performed using one-way ANOVA and Tukey's tests. * P < 0.05, ** P < 0.01, *** P < 0.001 vs STD group.
in Sprague-Dawley rats, [16, 23] d-fagomine partially counteracted the body weight gain induced by the HF diet in the long term ( Figure S1 , Supporting Information). Plasma insulin levels also increased in animals fed the HF diet after 10 weeks of intervention (Figure 1 ). High plasma insulin levels define the first of the five stages of diabetes proposed by Weir and Bonner-Weir for both rats and humans. [1] This compensation stage is characterized by increased overall rates of insulin secretion, via a greater number or size of pancreatic β-cells, in response to the loss of insulin sensitivity in tissues. d-Fagomine, which had shown a tendency to reduce insulin levels in the short term, [16, 23] did not have an influence on insulin levels after 10 weeks of our intervention ( Figure 1B) .
Later on, at the end of the study, the levels of fasting insulin in the HF group (without supplementation) dropped significantly ( Figure 1B) , while fasting glucose levels were still moderately high ( Figure 1A ). This situation is compatible with the second stage in the diabetes progression, which is characterized by a loss of β-cell mass and disruption of pancreatic function.
[1] Animals supplemented with d-fagomine did not seem to reach this second prediabetic stage, as their insulin levels remained high (Figure 1B) and their fasting glucose levels were similar to those of the STD group ( Figure 1A) . The second prediabetic state is also compatible with the IGT recorded in rats fed the HF diet, which already showed the classic plateau-like prediabetic curve after just 13 weeks. d-Fagomine counteracted this fat-induced IGT pattern as the supplemented rats removed glucose from their blood at a normal rate (Figure 2A,B) . By the end of the study (21 weeks), the AUC for the HF+FG and STD groups were still not significantly different. The evidence presented here, together with our previous observations of the short-term reduction in the early increase of fasting insulin concentration, [16, 23] shows that rats supplemented with d-fagomine always seem to be one step behind in the development of diet-induced prediabetes. Comparisons were performed using χ 2 statistics. *** P < 0.001 vs STD group; δδδ P < 0.001 vs HF+FG group.
We next considered through what mechanism or mechanisms d-fagomine exerts this functional metabolic effect. As d-fagomine reduced IGT more dramatically than it reduced body weight gain, we hypothesized that it may delay the development of diabetes in Wistar Kyoto rats by a mechanism that is not directly dependent on lipid accumulation. The results from our DAG analysis and histological study support this explanation. IR has been linked to ectopic fat through the action of DAGs, which are intermediates of lipid metabolism with the capacity to impair intracellular insulin signaling in both liver and muscle. [2] It has been proposed that DAGs interrupt the translocation of the glucose transporter GLUT4 to the plasma membrane by modifying the phosphorylation pattern of the intracellular insulin receptor substrate (IRS) after attaching to protein kinase C. [24] We evaluated total DAGs and the levels of selected molecular species in these two organs as well as in AT ( Figure 3 ). As there is no information to date as to what particular DAG species might impair insulin signaling, particular DAGs were chosen on the basis of their selective interaction with the cellular PKC-Ca 2 + signaling network. [25] Systemic IR in our model does not seem to be triggered by DAG-mediated impairment of insulin signaling, as the levels of total and selected DAGs in AT, liver, and muscle did not increase in either of the groups fed the high-fat diet ( Figure 3) ; in fact, DAG levels were even lower in some instances. The liver histology supported the hypothesis that direct lipid-mediated loss of insulin sensitivity was probably not a triggering factor of the early prediabetic stage in our model, as significant steatosis was not detected ( Figure 4D ). In contrast, strong lymphocyte infiltration indicated inflammation around the blood vessels ( Figure 4B ) which was greatly attenuated in animals supplemented with d-fagomine ( Figure 4C ). Lobular inflammation and numbers of microgranulomas were significantly higher in the HF group than in the STD group, while these levels in animals supplemented with d-fagomine were no different from those in the STD group ( Figure 4D ). The histology did not detect any sign of inflammation in AT and d-fagomine did not have any observable effect of fat-induced adipocyte hypertrophy ( Figure S3 , Supporting Information). All these results suggest that d-fagomine has a functional effect on HF diet-induced low-grade systemic inflammation that is independent of lipid accumulation. This hypothesis is supported by our additional measurements of the systemic inflammatory marker IL-6 and its related eicosanoid PGE 2 , a strong pro-inflammatory secondary metabolite from the oxidation of ARA catalyzed by cyclooxygenase-2 (COX-2) [26] which induces the production of IL-6 via macrophages. [27] The levels of IL-6 and PGE 2 were significantly higher in the HF group than in the STD group and were significantly reduced in the HF+FG group (Table 2). Also, the levels of LTB 4 , another pro-inflammatory ARAderived metabolite, were significantly lower in the supplemented group compared to the HF group ( Table 2 ). The fact that no www.advancedsciencenews.com www.mnf-journal.com Comparisons were performed using one-way ANOVA and Tukey's tests or two-way ANOVA. * P < 0.05, ** P < 0.01 vs STD group; $$ P < 0.01 vs STD group week 9. differences were detected in the levels of putatively antiinflammatory EPA-and DHA-derived eicosanoids and docosanoids (Table 2) suggests that d-fagomine exerts its functional effect when inflammation first occurs and not by activating anti-inflammatory pathways.
We next turned to how d-fagomine counteracts fat-induced low-grade inflammation. Gut microbiota may be the answer, or at least part of the answer. Gut dysbiosis is known to induce endotoxemia and low-grade inflammation in the host [3] through disruption of the intestinal barrier properties and release of proinflammatory molecules, such as LPS, into the bloodstream. [28] Chronic subclinical inflammation has been associated with insulin insensitivity [29] and suggested as a link between gut dysbiosis and early IR. [7, 11, 28] We have already suggested that the effect of d-fagomine on body weight gain and glycemic status may be related to a reduction in the overgrowth of gut Enterobacteriales induced by a high-energy-dense diet in the short term (up to 5 weeks). [23] The results presented here show that www.advancedsciencenews.com www.mnf-journal.com this explanation may hold in the long term, as the population of Enterobacteriales in the STD and HF+FG groups experienced no significant changes throughout this study ( Figure 5C ,G). Moreover, d-fagomine also showed a tendency to counteract the reduction in Bifidobacterium induced by the HF diet and age (HF and STD groups at week 24, Figure 5D ,H). The action of d-fagomine on Bifidobacterium may be connected to its capacity to eliminate Enterobacteriales, as the populations of these subgroups appear to be inversely related. [30] The hypothesis that d-fagomine exerts its anti-inflammatory and anti-diabetic action by balancing the populations of Enterobacteria and Bifidobacteria is backed by previous observations by others that link Enterobacteria to endotoxemia [6] and Bifidobacteria to a reduced impact of fat on diet-induced diabetes. [11] Bifidobacteria have also been inversely associated with obesity and age. [31] We also evaluated variations in the populations of Bacteroidetes and Firmicutes: the main two bacterial phyla in the intestinal tract ( Figure 5B,F) . A reduction in the Bacteroidetes:Firmicutes ratio has been related to a shift from lean to fat phenotypes in both rats and humans. [9, 32] Low levels of fasting-induced adipose factor (Fiaf) and phosphorylated AMP-activated protein kinase (AMPK) may be responsible for the lipid accumulation effect associated with changes in gut microbiota. [33] We show here that an HF diet can reduce the Bacteroidetes:Firmicutes ratio concomitantly with a significant gain in body weight ( Figure 5B,F; Figure S1 , Supporting Information) while d-fagomine does not appear to modify this change ( Figure 5B,F) . This observation confirms that the moderate effect of d-fagomine on weight gain might be associated with the contribution from minor components of gut microbiota (e.g., Enterobacteriales) rather than with changes in the main phyla.
The observation that the effects of d-fagomine on fat-induced changes in Enterobacteriales and Bifidobacteriales were moderate compared to the more dramatic effects on glucose tolerance and inflammation suggests that other microorganisms may be involved. We have also recorded an increase of plasma LPS in the d-fagomine supplemented group (Table 2) . Although LPS are usually associated with the stimulation of the inflammatory response, there is evidence that different LPS produced by different bacteria could either stimulate or actively inhibit inflammation. [34] A more thorough examination of the composition of gut microbiota, the gut barrier function, blood LPS composition, and the role of other mediators (e.g., biliary acids) in animals fed HF diets supplemented, or not, with d-fagomine would be the next step to take along this line of enquiry. Thus, d-fagomine may help to shed more light on the complex relationships between gut microbiota and metabolic alterations.
The mean daily dose of d-fagomine (29 mg per kg body weight) consumed by the rats in this study would translate to 4.6 mg per kg body weight in humans by following the conversion proposed by Reagan-Shaw et al. [35] This dose could be reached by supplementing the diet rather than relying on the d-fagomine content in buckwheat-based foodstuffs. [14] In summary, a very early effect of d-fagomine against fatinduced systemic low-grade inflammation would explain why animals fed d-fagomine are always one step behind in the progression of prediabetes: first against the loss of insulin sensitivity, then against loss of β-cell mass and disruption of pancreatic function. This effect may be attributed, at least in part, to a tendency to counteract the changes induced by a high-fat diet in the populations of gut bacterial subgroups such as Enterobacteriales and Bifidobacteriales.
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